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ABSTRACT 
BACKGROUND: A significant increase in the myocardial abundance of 
Membrane-Type 1 Matrix Metalioproteinase (MT1-MMP) has been identified in 
patients suffering Dilated Cardiomyopathy (OeM). These increased levels likely 
contribute to OeM; however, the molecular basis for up-regulation of MT1-MMP 
in the context of OeM remains unknown. Of significant relevance, microRNAs 
fine-tune protein translation by interrupting ribonucleoprotein:mRNA complexes, 
inducing degradation, or more commonly, translational repression of the 
message. Therefore, the aim of this study was to identify an endogenous 
microRNA responsible for the specific alterations correlating with disease state, 
and demonstrate a method of translational regulation of MT1-MMP. 
METHODS AND RESULTS: To identify potential regulatory microRNAs, a 
bioinformatics approach was taken to examine the MT1-MMP transcript for 
putative interaction sites. As a result, miR-133a was selected for further 
investigation. Using a commercially available reporter vector, constructed by 
cloning the 3' untranslated region (UTR) of the human MT1-MMP transcript 
downstream of a luciferase open reading frame, miR-133a was confirmed to 
directly target MT1-MMP's 3'UTR and selectively reduce translation with a 
significantly high level of efficiency in HT1080 cells. Investigations continued in a 
myocardial fibroblast model of OCM, developed and validated by this laboratory, 
and through reverse-transcription quantitative PCR (RT-qPCR), have, most 
interestingly, identified miR-133a microRNA levels to be significantly reduced in 
OCM myocardial fibroblasts (n=5) when compared to normal (n=4). Utilizing 
tools for permanent over expression and inhibition of miR-133a, the present 
study has successfully demonstrated, by protein immunoblot, a significant 
reduction in MT1-MMP protein abundance with miR-133a over expression, as 
well as, a significant increase in MT1-MMP protein abundance with miR-133a 
knockdown, in both normal and DeM myocardial fibroblasts. These findings 
were not accompanied by any significant change in MT1-MMP mRNA levels, and 
did not elicit induction of an interferon response, determined by RT-qPCR. 
CONCLUSIONS: The present study identifies aberrant miR-133a microRNA 
expression in OeM, confirms MT1-MMP as a target of miR-133a and 
demonstrates a method of translational regulation of MT1-MMP by direct 
modulation of miR-133a in normal and OeM myocardial fibroblasts. These 
findings hold diagnostic and therapeutic relevance for one of the most urgent 
public health problems in the United States. 
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CHAPTER 1: INTRODUCTION 
A structural event in the progression of heart failure is myocardial 
extracellular matrix (ECM) remodeling. ECM remodeling is an important process 
in regulating the dynamic balance between degradation and deposition in which 
a critical family of proteolytic enzymes, the matrix metalloproteinases (MMPs), 
actively participate. Recent advances in the understanding of cardiovascular 
disease processes have identified specific changes in the abundance and activity 
of a common membrane bound form, Membrane-Type 1 MMP (MT1-MMP), 
which functions in the modification of matrix structural proteins, activation of other 
MMPs, and proteolytic processing of bioactive molecules including: growth 
factors, cytokines/chemokines and interleukins30• 
The most numerous cell type in the heart is the cardiac fibroblast. In several 
cardiovascular diseases (heart failure, thoracic aortic aneurysm, and myocardial 
infarction) these endogenous fibroblasts undergo a cellular phenotype change 
that is accompanied by an increase in MT1-MMP abundance and enhanced 
ECM remodeling8,21,46. Elucidation of these diverse functions has also revealed 
that MT1-MMP can act on pro-inflammatory cytokines/chemokines and other 
proteins to regulate various aspects of the inflammatory response2S,33. Together, 
these studies suggest that MT1-MMP may be a turnkey mediator of ECM 
1 
remodeling in cardiovascular disease, and suggest that strategies targeting this 
protease may have significant clinical implications. 
Recently, microRNAs, a class of small, non-coding RNA, function to fine tune 
protein translation by interaction with the 3'-untranslated region (UTR) of targeted 
mRNAs, have been identified as endogenous upstream regulators of MMPs and 
have been promoted as potential therapeutics for heart disease6,21,4o. Aberrant 
microRNA expression is a recognized pathogenic means of disease, and is 
emerging as a clear mechanism mediating changes in ECM remodeling 
pathways; however, whether and to what degree microRNAs regulate the 
translation of MT1-MMP remains uncharacterized. Incidentally, through 
bioinformatic examination of MT1-MMP transcript, a putative miR-133a binding 
site was identified within the 3'-UTR. Therefore, by utilizing a cellular model of 
primary myocardial fibroblasts isolated from left ventricular biopsies of normal 
(n=4) and dilated cardiomyopathy (DCM) patients (n=5), this study has identified 
that endogenous miR-133a levels influence critical steps in extracellular matrix 




Endogenous miR-133a levels influence critical steps in extracellular matrix 
remodeling and cellular phenotype through the modulation of MT1-MMP protein 
abundance in normal and DeM LV myocardial fibroblasts (Figure 1-1). 
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Figure 1-1 . Hypothesis: miR-133a levels influence critical steps in ECM remodeling and 
cellular phenotype throuqh the modulation of MT1-MM P protein abundance. 
3 
Specific Aims 
1) Demonstrate DCM fibroblasts have a unique phenotype compared to 
normal fibroblasts. Utilizing primary myocardial fibroblast cultures: 
demonstrate differential steady-state MT1-MMP expression, ribosomal 
distribution (translational efficiency), protein abundance, and activity. 
2) Establish miR-133a as a post-transcriptional regulator of MT1-MMP. a) 
Demonstrate that Normal and DCM myocardial fibroblasts can be transfected 
by viral vectors to over express miR-133a or anti-miR-133a. b) Following 
transduction, determine the presence of an activated non-specific cellular 
stress response elements. c) Establish the mechanism by which miR-133a 
regulates MT1-MMP protein abundance by quantifying MT1-MMP transcript 
levels and ribosomal distribution. 
3) Determine the effect of miR-133a modulation on phenotypic differences 
between normal and DCM fibroblasts. Through the viral-mediated over 
expression of miR-133a or anti-miR-133a demonstrate that: a) in normal 
fibroblasts, the knockdown of miR-133a enhances MT1-MMP protein 
abundance and activity, inducing the phenotypic differences as defined in 
specific aim 1; while b) in DCM fibroblasts over expression of miR-133a 
suppresses MT1-MMP protein abundance and activity, and returns the cells to 
a "normal phenotype" as defined in specific aim 1. 
4 
CHAPTER 2: REVIEW OF LITERATURE 
Clinical Significance 
Cardiovascular disease (CVD) represents a leading cause of morbidity and 
mortality, emphasizing the need for innovative therapies and diagnostics37 . One 
in three American adults has some form of CVD21. Heart disease and stroke are 
the most common forms, and are leading causes of death for both men and 
women in the United States37 (Figure 2-1); however, current indicators suggest 
460,000 
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Figure 2-1. Cardiovascular disease and other major causes of death for all males and 
females. A, cardiovascular disease plus congenital cardiovascular disease; B, cancer; C, 
accidents; 0, chronic lower respiratory disease; E, diabetes mellitus; F, Alzheimer disease. 
Source: National Center for Health Statistics and National Heart, Lunq, and Blood Institute. 
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there has been a relative shift away from drug development for heart failure by 
the pharmaceutical industry. This is believed to be result of multiple failures late 
in the clinical trial process for a number of pharmacological agents, including 
those for TNF blockers3 and even most of the MMP inhibitors22. CVD is defined 
as an abnormal function of the heart and/or blood vessels. The causes of CVD 
range from structural defects to infection, inflammation as well as environmental 
and genetic factors. CVD can cause an increase in risk for heart attack, heart 
failure, sudden death, stroke, cardiac rhythm problems, and aortic aneurysms, 
thus resulting in diminished quality of life and decreased life expectancy. 
Heart failure (HF) is the pathophysiologic state diagnosed using a confluence 
of symptomology, in which the heart fails to pump blood at a rate commensurate 
with the requirements of the metabolizing tissues. One such example of disease 
is dilated cardiomyopathy (DeM) (Figure 2-2), and is characterized by dilation of 
the left ventricle (LV) and impaired pump contraction of the affected ventricle 
resulting in progressive heart failure 11. The compliance of the LV myocardium is 
determined by the physical properties of the cardiac muscle and other tissues 
making up the ventricular wall. Alterations in cardiovascular stress initiate a 
multifaceted response in the LV to attempt normalization of the imposed strain? 
This response can include alteration in cellular shape and changes in the amount 
and type of collagen as well as degree of collagen cross-linking42. Frequently 
these changes are associated with decreased ventricular compliance, which 
results in the progressive reduction of normal cardiac pump function. If 
continued elevation in wall stress exceeds the ability of the heart to compensate, 
6 
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Figure 2-2. Illustration of normal and OeM. A OCM heart illustrating characteristic dilation of 
the left ventricle, and disproportionately reduced ventricular wall thickness (Right). A normal 
heart is illustrated on the left for comparison. Gross anatomical and pathological illustrations by 
Cathryn T. Akerman. 
then the ventricular wall thickness is disproportionately reduced compared to 
chamber volume and diastolic and systolic dysfunction ensues43. 
The overwhelming majority of patients diagnosed are described as having 
acquired an idiopathic DCM, a disease of unknown cause21 . Specific treatments 
are not available for most patients with idiopathic DCM 11 . Therefore, the primary 
aims of the limited current therapeutic goals are to relieve/stabilize associated 
symptoms and prolong survival by halting or reversing the progression of 
myocardial dysfunction20. To gauge the current extent and focus of federally and 
privately supported clinical trials in heart failure, conducted within the United 
7 
States and around the world, the NIH Clinical Trials Registry was examined. 
This database identified 74 ongoing clinical trials in 2011, with a principal focus 
on heart failure. Of these trials, 23% were device based and 15% were 
procedure based trials, with primary focuses on addressing modifications of 
existing biventricular pacing and automatic implantable defibrillator technology, 
telemonitoring devices, or evaluating the utility of new devices for the delivery of 
cell therapy24. Interestingly, only 8% of the studies are based on the actual 
delivery of biological based therapeutics. The remaining 54% of trials evaluating 
pharmacotherapy for heart failure are directed toward evaluation of treatment 
efficacy. Treatment of heart failure targets early steps in signaling pathways, 
such as cell surface receptors, calcium channels, handling proteins, and 
components of the ~-adrenic receptor system51 ; however, given the multitude of 
signals contributing to the progression of myocardial dysfunction, single target 
therapy has proven to be insufficient. Therefore, an alternative approach that 
targets multiple pathways within complex disease phenotypes may be more 
efficacious. 
Pathophysiology of OeM: changes in extracellular matrix 
The changes in myocardial structure and function leading to the progression 
of OCM result from the combined actions of cellular and extracellular factors 
which govern the constitution of the extracellular matrix (ECM) and playa critical 
role in the homeostatic remodeling process. Collagens, the chief components of 
the ECM, are a tightly regulated family of proteins that determine the structural 
8 
and functional integrity of the heart. The dynamic balance between ECM 
degradation and deposition is mediated by a family of proteolytic enzymes 
capable of degrading all ECM components, the matrix metalloproteinases 
(MMPs). Several MMP types have been identified within the human myocardium 
to be pathologically dysregulated in OCM44. For example, MMPs that are 
expressed at very low levels in normal myocardium, such as, gelatinase A 
(MMP2) and membrane-type 1 (MT1) MMP (MT1-MMP), are substantially up 
regulated. The MMPs are produced by both the endogenous cells within the 
myocardium (myocytes, fibroblasts), as well as the infiltrating inflammatory cells 
(macrophages, neutrophils, 8-cells, T-cells). 
Past studies involving histological and biochemical analyses of OCM have 
provided the foundation and rationale for identifying a direct relationship between 
myocardial remodeling and matrix metalloproteinase (MMP) induction and 
activation within the myocardium of patients suffering from heart failure43,44,45. In 
particular, the available experimental data indicate the trans-membrane topology 
of MT1-MMP may allow this enzyme the unique ability to profoundly influence the 
ECM through direct involvement with remodeling and, in parallel, actively 
participate in the signaling events involved in the cell response to these 
modifications 14. 
Of all the MT-MMPs, MT1-MMP is the best characterized. MT1-MMP is a 
fully active enzyme once inserted into the cell membrane and contains an 
extracellular catalytic domain, hinge region, hemopexin-like repeat domain, stem, 
9 
a transmembrane domain, and an intracellular cytosolic tail, all of which are 
critical for full functioning of the protease (Figure 2-3). 
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Figure 2-3. Domain structure and location of active MT1-MMP. H, hemopexin-like 
domain; TM, trans-membrane domain; CT, cytosolic tail. 
Membrane Type 1-MMP has been shown to play a critical role in the 
pericellular degradation of connective tissue matrix by directly hydrolysing native 
collagen I, and indirectly by initiating a cascade of zymogen activation at the cell 
surface, which leads to the generation of active MMP2. MT1-MMP also 
degrades a variety of surface associated proteins, including growth factors, 
cytokines and cell adhesion receptors, further indicating its function as a major 
mediator of surface proteolysis. 
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A control point for MMP activity is through the inhibition of the activated 
enzyme by the action of a group of specific MMP inhibitors known as the Tissue 
Inhibitors of Metalloproteinase (TIMPs), of which there are four known species. 
TIMPs bind to the catalytic domain of active MMPs, preventing access to 
substrates. Figure 2-4 demonstrates the complex formed by the MT1-MMP with 
TIMP-2. 
Figure 2-4 . Space fill view of the MT1-MMP:TIMP-2 complex. MT1-MMP catalytic domain 
(PURPLE), TIMP-2 (BLUE). Figures drawn with MMDB (Madej, 2012). 
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Previous studies performed by this laboratory have identified that myocardial 
MT1-MMP protein abundance is elevated in the left ventricle of patients with 
DCM44 (Figure 2-5). These increased tissue levels of MT1 -MMP protein likely 
Myocardial MTI-MMP Protein Abundance 
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Figure 2-5. MT1-MMP protein abundance is elevated in the left ventricular myocardium of 
OCM (n=21) patients compared to normal (n=13). Source: Circulation 102; 2000. 
contribute to changes in matrix structure and function in the DCM myocardium. 
These past investigations, while of great significance, were limited to the abil ity of 
only providing insight into the cellular and molecular basis for altered myocardial 
MMP activity occurring in end-stage human heart failure, and moreover, 
demonstrate the importance of new large animal models and translational studies 
designed to target the underlying mechanisms which contribute to the 
progression of disease. 
The myocardial fibroblast IS the most numerous cell type within the 
myocardium and functions as a key mediator of pericellular proteolysis critical in 
degradation of the ECM15. Therefore a potential therapeutic cell target would be 
to regulate myocardial fibroblast form and function . The directions of this study 
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include mechanisms' of cardiovascular remodeling with an emphasis on 
translational regulatory pathways that control unique enzymes in the extracellular 
space and contribute to changes in cellular phenotype and how this proteolytic 
pathway, known to promote cardiovascular disease, may be regulated. 
In human heart failure, such as DeM, increased and prolonged neuro-
hormonal activity and the release of biologically active molecules occurs, which 
culminates in the formation of a number of up-stream transcription factors, and in 
turn may induce prolonged changes in MMP and other pro-fibrotic gene 
transcription43• The MT1-MMP promoter region is unique from other MMP types 
in that it contains a number of distinct response elements. For example, three 
transforming growth factor (TGF) inhibitory elements (TIEs) which bind the family 
of Smad transcription factors, and one GC box which binds SP1 transcription 
factors, have been identified45 (Figure 2-6). 
-753 -664 -597 -552 -540 -370 -148 -92 
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Figure 2-6. MT1-MMP promoter region. CCAAT (or ATTGG), CCAAT box; TIE, 
Transforming growth factor inhibitory element; GC, SP1 binding site. 
Following transcription and subsequent nuclear export, a number of post-
transcriptional steps are required for insertion of MT1-MMP into the cell 
membrane as well as release of soluble MMP2. The activation of the soluble 
MMP2 requires proteolytic cleavage of the prodomain, which occurs primarily by 
MT1-MMP. This activation step provides for focal proteolytic activity, but can 
quickly amplify as additional MT1-MMP or soluble MMP2 is synthesized43• 
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In addition to MT1-MMP's ability to directly activate pro-inflammatory 
cytokines33, it has also been demonstrated that interaction with the Latent 
Transforming Binding Protein-1 (L TBP-1) resulting in the release of active 
Transforming Growth Factor ~ (TGF-~). The TGF- ~ superfamily plays a critical 
role in the regulation of cell growth, differentiation and development in normal 
and pathological development. Signaling is initiated with ligand-induced 
oligomerization of serine/threonine receptor kinases and phosphorylation of the 
cytoplasmic signaling molecules Smad2 and Smad3. Carboxy-terminal 
phosphorylation of Smads by activated receptors results in their partnering with 
the common signaling transducer Smad4, and translocation to the nucleus. 
Activated Smads regulate diverse biological effects by partnering with 
transcription factors resulting in cell-state specific modulation of transcription. 
Activation of Smad-independent pathways through TGF-~ signaling is also 
common. Rho GTPase (RhoA) activates downstream target proteins, such as 
mDia and ROCK, to prompt rearrangement of the cytoskeletal elements 
associated with cell spreading, cell growth regulation, and cytokinesis46. Figure 
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Figure 2-7. MT1-MMP's key role in the development of Dilated Cardiomyopathy. The 
changes in myocardial structure and function leading to the progression of OCM result from 
the combined actions of cellular and extracellular factors which govern the constitution of the 
extracellular matrix (ECM) and playa critical role in the homeostatic remodeling process. 
Summary: Clinical Significance 
A significant increase in the myocardial abundance of MT1-MMP has been 
identified in OeM patients, and these increased levels likely contribute to OeM; 
however, the molecular basis for the up-regulation of MT1-MMP in the context of 
oeM remains unknown. Since OeM is a progressive myocardial disease 
process that culminates in severe heart failure and hemodynamic collapse, 
mechanical assist devices and/or heart transplantation are often required. As 
such, access to myocardial samples from OeM patients is possible and has 
15 
allowed for an extensive survey of MT1-MMP. The myocardial fibroblast is the 
most numerous cell type within the myocardium and functions as a key mediator 
of pericellular proteolysis critical in degradation of the ECM. Therefore a 
potential therapeutic cell target would be to regulate myocardial fibroblast 
phenotype through modulation of MT1-MMP protein abundance. 
16 
INNOVATION 
This novel study characterizes a method of post-transcriptional regulation of 
MT1-MMP protein abundance by direct modulation of a particular microRNA, 
miR-133a, known to be enriched in cardiac and skeletal muscle, and involved in 
cell specification, differentiation, and development5,1o. MicroRNAs have recently 
been identified as new putative therapeutics for heart disease6, and are also 
known endogenous upstream regulators of MMPS6,21,34. MicroRNAs, a class of 
naturally-occurring, small non-coding RNAs, are highly conserved among 
species, and fine-tune protein translation by interrupting ribonucleoprotein:mRNA 
complexes, inducing degradation, or more commonly, translational repression of 
the message34• Of significant relevance, aberrant microRNA expression is a 
recognized pathogenic mechanism of disease, and is beginning to be identified 
as key in regulation of specific proteins involved in extra cellular matrix 
remodeling pathways. 
MicroRNA biogenesis is outlined In Figure 2-8, and illustrates an 
endogenous mechanism of translational regulation. The impact of microRNA 
mediated biological regulation is vast. It is estimated that microRNAs post-
transcriptionally regulate over 60% of all protein coding genes23• An especially 
powerful feature of microRNA mediated regulation is the ability of a single 
microRNA to regulate multiple functionally related mRNAs. The targeting of 
multiple mRNAs that participate in common cellular processes contrasts with the 
approach of most drug therapies, which are directed at highly specific targets, 
and enables microRNAs to effectively regulate complex intracellular pathways, 
17 
thereby potentially avoiding redundant mechanisms that may bypass a single 
inhibited target. 
Figure 2-8. microRNA Biogenesis and Mechanism of Gene Regulation. Like all classes of 
RNA, microRNAs are transcribed from DNA. Like mRNAs, this nuclear process is RNA 
polymerase II dependent and regulated by transcription factors (1.). If the gene transcribed 
encodes a protein, the result is messenger RNA (mRNA), which will then be used to create that 
protein in the process of translation. Alternatively, particular non-gene coding regions as well as 
non-protein coding portions of DNA transcriptional units, such as introns, may be transcribed to 
produce translational regulatory sequences. Transcription generates a long primary transcript, 
termed the primary microRNA (2.). Following transcription, microRNA processing continues with 
hydrolysis of the transcript by the enzyme Drosha to produce a precursor microRNA (3.), which 
then interacts with Exportin-5 (XPO-5) (4.) and is then exported from the nucleus to the cytoplasm 
(5.) where further hydrolysis by the Dicer Ribonuclease removes the loop portion of the precursor 
microRNA (6.), generating a double stranded microRNA duplex (7.). In the cytoplasm, final 
processing occurs as the microRNA duplex interacts with Argonaut (AGO) protein (8.) and is 
stripped of its complementary passenger strand (9.). Incorporation of accessory protein, GW182, 
forms the RNA-Induced Silencing Complex (RISC), which can interact with the 3'UTR of target 
mRNAs (10.) resulting in two possible outcomes. Dependent upon the level of homology 
between the microRNA and targeted mRNA sequences: if the homology is high, the targeted 
mRNA transcript is degraded (11.); or if the homology is low, imperfect base paring between the 
microRNA and mRNA results in translational repression (12.). The latter outcome occurs in 85% 
of interactions. In this scenario the RISC Complex functions by using the incorporated mature 
microRNA sequence as a target recognition component. This allows for imperfect interaction with 
complementary binding sites predominantly located in the 3' UTR of a targeted mRNA and results 
in translational repression of that particular message. 
18 
MicroRNAs interfere with translation by interaction with the 3'UTR. It is 
believed that the RiSe complex inhibits translation initiation by interfering with 
elF4F-cap recognition and 40S small ribosomal subunit recruitment or by 
antagonizing 60S subunit joining and preventing 80S ribosomal complex 
formation. Ding et al. reported that an interaction of the GW 182 protein with the 
poly(A)-binding protein (PABP) might interfere with the closed-loop formation of 
the mRNA, mediated by the eIF4G-PABP interaction, and thus contribute to the 
repression of translation initiation 10. 
Summary: Innovation 
An especially powerful feature of microRNA based regulation is the ability of 
single microRNAs to regulate multiple functionally related mRNAs6. The 
targeting of multiple mRNAs that participate in common cellular processes 
contrasts with the approach of most drug therapies, which are directed at highly 
specific targets, and enables microRNAs to effectively regulate complex 
intracellular pathways, thereby potentially avoiding redundant mechanisms that 
may bypass a single inhibited target. This however raises concern over the 
possibility that the targeted modulation of a particular microRNA may, at the 
same time, interfere with beneficial cellular functions6. While a great deal 
remains to be understood, the concept of microRNA manipulation to regulate 
complex disease related processes is becoming a feasible future therapeutic 
approach6. Moreover, identification of an endogenous microRNA that may 
influence critical steps in extracellular matrix remodeling pathways of myocardial 
19 
fibroblasts through modulation of MT1-MMP protein abundance, and subsequent 
elucidation of the cellular and molecular pathways responsible for the specific 
alterations correlating with heart failure holds diagnostic and therapeutic 
relevance for one of the most urgent public health problems in the United States. 
20 
CHAPTER 3: PRELIMINARY STUDIES 
Previously, this laboratory has determined that MT1-MMP protein levels are 
increased in the tissue associated with several cardiovascular diseases, and 
these specific differences were replicated in fibroblast cultures43. Flack et. al. 
demonstrated that the myocardial fibroblasts isolated from a large animal model 
of pacing induced LV failure exhibited quantifiable phenotypic alterations 
persistent throughout sub-cultivation in the absence of external biological or 
physical stimuli when compared to normal13. Therefore, investigations continued 
in a myocardial fibroblast model of OCM, developed and validated by this 
laboratory. Accordingly, LV biopsies from non-failing, reference normal patients 
possessing a >50% LV ejection fraction, undergoing elective coronary bypass 
surgery and possessing no perfusion defects at site of biopsy (n=4), and end-
stage DeM patients with an LV ejection fraction of <20% at time of transplant 
(n=5), were extracted and used to establish primary fibroblast cultures. The 
biopsies were extracted from the same region of the LV, and were processed for 
culture in an identical fashion. Cell cultures were confirmed to be pure fibroblasts 
by immunochemistry using antisera against a panel of antibodies and were 
positive for actin, which is selectively bound by phalloidin51 ; the discoidin domain 
receptor 2 (DDR2), DDR2 protein expression is confined to fibroblasts, and is not 
expressed on myocytes, endothelial or smooth muscle cells 16; and prolyl-4-
21 
hydroxylase, an enzyme involved in the synthesis of collagens; but were negative 




Figure 3-1. Cell cultures were confirmed to be pure fibroblasts by immunochemistry using 
antisera against a panel of antibodies and were positive for actin (phalloidin), the discoidin 
domain receptor 2 (DDR2) and prolyl-4-hydroxylase but were negative for smooth muscle 
myosin heavy chain. DAPI was used as a nuclear counterstain (blue). 
for this panel of antisera was performed routinely on cell passages to ensure 
phenotypic stability with respect to these fibroblast markers. The isolated 
myocardial fibroblasts were maintained in complete fibroblast specific growth 
media (PromoCell) with added 10% Fetal Bovine Serum (Gibco), antimycotic 
Amphotericin B (5 ug/mL) and the aminoglycoside antibiotic, Gentamicin (0.5 
mg/mL) at 37°C in 5% CO2 . Utilizing this approach, confluent LV fibroblasts from 
culture passages 2-8 were measured with respect to MT1-MMP protein 
abundance and activity, as well as MT1-MMP mRNA levels and ribosomal 
distribution. 
For this purpose, myocardial fibroblast cultures were grown to confluence in 
sterile T-75 Falcon culture flasks with complete fibroblast growth media then 
washed once with D-PBS, with calcium and magnesium, and then serum starved 
in FBS reduced fibroblast growth media overnight. Growth Media was then 
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aspirated and cells were collected uSing a PBS-based, enzyme-free, cell-
disassociation buffer. Collection of cells by this method preserves the structural 
and functional integrity of cell surface proteins 18. Whole cell pellets were 
collected under steady state conditions, and MT1-MMP abundance was 
assessed by immunoblotting in the following fashion. Equal amounts of total 
protein (1 Dug), extracted from the cell pellet, were loaded onto 10% 
polyacrylamide gels and transferred onto nitrocellulose membranes. After 
blocking for 1 hour in 5% milk at room temperature, the membranes were 
incubated for 1 hour at 37°C In primary anti-sera for Human MT1-MMP 
hemopexin domain (AB8221). As shown in Figure 3-2, MT1-MMP protein levels 
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Figure 3-2. MT1-MMP Protein Abundance. MT1-MMP protein abundance is significantly 
elevated in LV myocardial fibroblasts isolated from OeM patients when compared to normal. 
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were found to be significantly elevated in sub-cultivated OCM myocardial 
fibroblasts as compared to normal. To verify that the observed increase in MT1-
MMP protein abundance correlated with proteolytic activity in OCM, the amount 
of active MT1-MMP was quantified in whole cell homogenates using a specific 
fluorescent resonance energy transfer peptide substrate, where in the intact 
peptide, fluorescence is quenched. Upon hydrolysis of the peptide sequence by 
MT1-MMP, the quenching group separates from the fluorophore allowing 
fluorescence to be quantitated. Results from this assay demonstrate that MT1-
MMP specific activity over a 15 hour period of time, was indeed increased In 








In 200 M 
----C» 
U 150 C 
C» 
u Normal '" C» ... 
0 
::J -1.1. 
o 1 4 6 8 10 12 14 16 
Time (hrs) 
Figure 3-3. MT1-MMP Activity. MT1-MMP activity is significantly elevated in LV myocardial 
fibroblasts isolated from OeM patients when compared to normal. Data are represented as 
mean (solid line) +/- standard error of the mean (shaded regions). 
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Little is known about the transcriptional and translational regulatory 
mechanisms controlling MT1-MMP protein abundance in human myocardial 
fibroblasts. In consequence, MT1-MMP mRNA levels were assessed by 
quantitative RT-PCR during steady state conditions. Cells were grown to 
confluence in sterile 60mm Falcon culture dishes with complete fibroblast growth 
media then washed once with D-PBS and serum starved in FBS reduced 
fibroblast growth media for 24 hours. Growth Media was then aspirated and cells 
were lysed directly in RL T plus lysis buffer (Qiagen) with added 2-
Mercaptoethanol (10/0) to eliminate ribonucleases released during cell lysis. Total 
RNA was then isolated and purified using the Qiagen RNeasy Plus kit with 
Genomic DNA (gONA) eliminator spin column, and determination of total RNA 
purity and concentration was performed using The Experion RNA StdSens 
analysis kit (Caliper Life Sciences, Inc. Bio-Rad Laboratories). Total RNA was 
reverse transcribed with the modified MMLV-derived reverse transcriptase and 
blend of oligo(dT} and random hexamer primers contained in the iScript cDNA 
Synthesis Kit (BioRad). Single-stranded cDNA was synthesized from 1 ug total 
RNA in 20 uL reaction volume with iScript eDNA SyntheSiS Kit (BioRad), 
according to the manufacturer's protocol. The reaction was incubated at 25°C for 
5 min followed by 30 min at 42°C and inactivation at 85°C for 5 min. Each cDNA 
was amplified with sequence-specific TaqMan Gene Expression Assays from 
Applied Biosystems. PCR reactions were performed on a Bio-Rad CFX96 Real-
Time System in 25 uL volumes in a 96-well plate at 95°C for 10 min, followed by 
40 cycles of 95°C for 15 sec and 60°C for 1 min. All samples were tested in 
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duplicate. The relative expression of each mRNA was calculated and normalized 
to the internal control 18S rRNA using the comparative cycle threshold (CT) 
method (Livak and Schmittgen, 2001). Relative expression intensity values were 
calculated as 2-~CT, in which ~CT are CT values normalized to the reference 
control. Consistent with elevated MT1-MMP protein abundance and activity, 
MT1-MMP mRNA levels were observed to be significantly elevated in OCM 
myocardial fibroblasts compared to normal (Figure 3-4). 
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Figure 3-4. MT1-MMP mRNA Levels. MT1-MMP mRNA is significantly elevated in LV 
myocardial fibroblasts isolated from OeM patients when compared to normal. 
To determine if increased MT1-MMP abundance in OCM fibroblasts may be 
due to alterations in translational efficiency, ribosomal fractionation studies were 
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performed. The fibroblasts were grown to confluence in sterile T-150 Falcon 
culture flasks with complete fibroblast growth media then washed twice with 4°C 
PBS, without calcium or magnesium, containing cycloheximide (10ug/ml). The 
fibroblasts were then collected by scraping, and dounce-homogenized in a 4°C 
buffer containing 10 mM Tris, pH 7.5, 250 mM KCl, 10 mM MgCb, 0.5% Triton 
X-100, 2 mM DL-Dithiothreitol (DTT) , 100 ug/ml cycloheximide, and 2 ul 
RNAsin (Promega). Tween-deoxycholate (20%) was added to the cell 
homogenate, then incubated for 15 min at room temperature, and then 
centrifuged at 4°C for 15 min at 13,000 g to produce a post-mitochondrial 
supernatant, which was then layered onto a 15-500/0 sucrose gradient containing 
20 mM Tris, pH 7.5, 250 mM KCl, 10 mM MgCI2, and 80 units of RNAsin. The 
samples were then subjected to ultracentrifugation at 100,000 g for 100 min at 
4°C, and gradients were fractionated on an Isca density gradient fractionator, 
yielding ten fractions of equal volumes (1 mL). The first five fractions of the 
gradient separation contain monosomes that include free 40S and 60S ribosome 
subunits, and mRNAs assembled into messenger ribonucleoprotein (mRNp)43. 
The next 5 fractions contain polysomes, which consist of mRNAs that are active 
in translation. The RNA was then extracted and purified from each fraction and 
MT1-MMP and glyceraldehydes-3-phosphate dehydrogenase (GAPDH), one of 
the most commonly used housekeeping genes in comparisons of gene 
expression data, mRNA levels were determined by RT-PCR as described in the 
preceding section. Total translational capacity and ribosomal abundance was 
taken into account by normalizing the individual mRNAs of interest (MT1-MMP 
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and GAPDH) to the 188 ribosomal RNA (rRNA) subunit. The entire distribution 
of MT1-MMP and GAPOH mRNAs across both monosomal and polysomal 
fractions were examined. For this approach, the first half of the gradient 
(fractions 1-5) were considered monosomal and the second half (fractions 6-10) 
were considered polysomal. This categorical approach accounts for small shifts 
in the resolution of adjacent polysome fractions, following sucrose gradient 
centrifugation, within each experiment. Relative expression intensity values were 
calculated as 2-~CT, in which ~CT are CT values normalized to the reference 
control, and the data is presented as a percent of total mRNA distributed. These 
preliminary observations demonstrate MT1-MMP mRNA in normal myocardial 
fibroblasts is largely within monosomal fractions; however, in OeM myocardial 
fibroblasts, MT1-MMP mRNA is predominantly within polyribosomal fractions 
(Figure 3-5). These observations suggest an increase in MT1-MMP translational 
efficiency in DeM myocardial fibroblasts. To demonstrate that increased 
translational efficiency is not a global characteristic of OCM, GAPOH mRNA 
across both monosomal and polysomal fractions was examined in an identical 
fashion. In both normal and OCM myocardial fibroblasts, GAPOH mRNA is 
predominantly within monoribosomal fractions (Figure 3-6). Combined, these 
findings suggest that specifically MT1-MMP translational efficiency is highly 







Figure 3-5. MT1-MMP Ribosomal Distribution. MT1-MMP mRNA in normal myocardial 
fibroblasts is largely within monosomal fractions. In OCM myocardial fibroblasts, MT1-MMP 















Figure 3-6. GAPDH Ribosomal Distribution. In both normal and OCM myocardial 
fibroblasts, GAPOH mRNA is predominantly within polyribosomal fractions 
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Summary: Preliminary Studies 
As myocardial fibroblasts, harvested and expanded in culture from patients 
with end-stage OCM, exhibit persistent alterations in signaling, transcriptional 
and post-translational pathways requisite for MT1-MMP processing26 , the present 
study will move beyond in vivo observational investigations of MT1-MMP and 
demonstrate modulation of the molecular signals and pathways that cause 
persistent abnormalities in matrix degradation pathways in a human myocardial 
cellular model of OCM. This will allow for the resolution of the described aims 
and hypothesis that miR-133a levels influence critical steps in ECM remodeling 
and cellular phenotype through the modulation of MT1-MMP protein abundance 
(Figure 3-7). 
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Figure 3-7. Hypothesis: miR-133a levels influence critical steps in ECM remodeling and 
cellular phenotype throuqh the modulation of MT1-MMP protein abundance. 
30 
CHAPTER 4: RESULTS AND DISCUSSION 
Experimental Design: Currently, there is limited research indicating 
successful post transcriptional control of MT1-MMP with a single, specific 
microRNA. The studies described above have provided the mechanistic and 
methodological structure for the work that follows. Outcomes from this set of 
investigations demonstrate post-transcriptional regulation of a key proteolytic 
mediator of ECM remodeling, MT1-MMP, by miR-133a, and furthermore 
determine the effects of modification on the phenotypic differences observed in 
DeM myocardial fibroblasts. The stepwise approach: 1) defines the phenotypic 
differences associated with determinants of ECM structure and function in DCM 
myocardial fibroblasts; 2) establishes miR-133a as a post-transcriptional 
regulator of MT1-MMP; and 3) demonstrates that in vitro modulation of miR-133a 
can alter the defined phenotypic differences in OeM myocardial fibroblasts. 
These studies contribute to a better understanding of the etiology of OeM 
disease, and identify a modifiable endogenous regulatory target that may provide 
the foundation for the development of novel therapeutics with the potential for 
returning OeM phenotypic differences to normal. 
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In order to identify potential regulatory microRNAs of MT1-MMP, a 
bioinformatic approach was taken to examine the MT1-MMP transcript for 
potential microRNA interaction sites. A TargetScan Human analysis, which is a 
widely used predictor of biological targets of microRNAs, identified 5 potential 
microRNA interactions, 3 of which were classified as 8mer targets meaning they 
possess an exact match to positions 2-8 of the mature microRNA followed by an 
adenosine molecule. This suggests a high likelihood for interaction, in that site 
conservation is defined by conserved branch length, with an 8mer interaction 
possessing the most stringent threshold conservation56. Upon further literature 
review of the three leading 8mer microRNAs identified, miR-133a was found to 
be enriched in cardiac and skeletal muscle and involved in cell specification, 
differentiation, and development. In addition, five other bioinformatics 
algorhythms (specifically: MicroCosm Targets Version 5; DIANA; PITA; RNA22; 
and RNAhybrid) identified miR-133a as a strong candidate for potential 
interaction with the same seed region of the MT1-MMP transcript (Figure 4-1). 
- Seed Region -
MT1-MMP 3' UTR 5 ' ... AGAGGGGGCAGGAGG G GACCAA ~ ... 
(position 925-931 ) I I I I I I I I I I I I 
miR-133a 3 ' GUCGACCAACUUCC C CUGGUU U 
Figure 4-1. miR-133a putative interaction site targeting the 3'UTR of MT1-MMP 
transcript. The 8mer interaction site showing an exact match to positions 2-8 of the mature 
miR-133a sequence followed by an adenosine molecule. 
Furthermore, RNAhybrid is a tool for a putatively calculated determination of the 
minimum free energy (mfe) hybridization of a long (3'UTR sequence) and a short 
RNA (mature microRNA sequence). This tool is primarily intended for use as a 
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means of microRNA target prediction by allowing the short sequence to hybridise 
to the best fitting part of the longer sequence30. RNAhybrid provided a schematic 
of miR-133a predicted binding within the MT1-MMP 3' UTR, and identified the 
putative interaction as having a relatively low mfe of -35.2 kcal/mol, further 
strengthening the possibility for interaction30 (Figure 4-2) Therefore, miR-133a 










Figure 4-2. miR-133a putative interaction site targeting the 3'UTR of MT1-MMP 
transcript. The 8mer interaction site showing an exact match to positions 2-8 of the mature 
miR-133a sequence followed by an adenosine molecule. The mfe of the predicted interaction 
is -35.2 kcal/mol. 
Current prediction algorithms calculate target efficacy based on interactions 
between the mRNA with itself and the mRNA with a microRNA; however, 
endogenously these interactions are occurring in a complex cellular environment 
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in which mRNAs and microRNAs are likely bound by cellular RNA-binding 
proteins, which is currently impossible to account for in silico. Therefore, 
investigation continued with quantification of miR-133a microRNA levels. Total 
RNA was reverse transcribed with looped microRNA-specific RT primers 
contained in the Taq-Man microRNA Human Assays (Applied Biosystems). 
Single-stranded cDNA was synthesized from 10 ng total RNA in 15-uL reaction 
volumes with TaqMan microRNA Reverse Transcription Kit (Applied 
Biosystems), according to the manufacturer's protocol. The reaction was 
incubated at 16°C for 30 min followed by 30 min at 42°C and inactivation at 85°C 
for 5 min. Each cDNA was amplified with sequence-specific TaqMan microRNA 
Assays from Applied Biosystems. peR reactions were performed on a Bio-Rad 
CFX96 Real-Time System in 20 uL volumes in a 96-well plate at 95°C for 10 min, 
followed by 45 cycles of 95°C for 15 sec and 60°C for 1 min. All samples were 
tested in duplicate. The relative expression of each microRNA was calculated 
and normalized to the small nucleolar RNA U47 (NR_002746.1) using the 
comparative cycle threshold (CT) method (Livak and Schmittgen, 2001). 
Relative expression intensity values were calculated as 2-~CT, in which ~CT are 
CT values normalized to the referent control. Most interestingly, miR-133a levels 
were found to be significantly reduced in LV myocardial fibroblasts isolated from 
DeM patients when compared to normal (Figure 4-3). As previously mentioned, 
aberrant microRNA expression is a recognized pathogenic means of disease, 
therefore, results from this finding would suggest miR-133a may playa role in the 
underlying pathogenesis. 
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Figure 4-3. miR-133a microRNA Levels. miR-133a levels are reduced in LV myocardial 
fibroblasts isolated from OeM patients (n=5) when compared to normal (n=4). 
MicroRNAs impact nearly all physiological pathways, including apoptosis, 
proliferation, pluripotency, differentiation, and cancer. In order to begin the 
process of unraveling the complex regulatory pathways governed by miR-133a, 
tools for permanent over expression and inhibition will be employed. It should be 
noted that while over expression or knockdown of a gene in a normal cell can 
provide invaluable insight regarding its function, normalizing its levels during a 
specific pathological condition is requisite for obtaining direct evidence regarding 
its role in the underlying pathogenesis. Therefore, to accomplish the proposed 
scientific objectives and investigate the role of miR-133a in OeM, a human 
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myocardial fibroblast model of OeM, developed and validated by this research 
group7t38t39, will be under investigation. The defined phenotypic differences 
observed in cultured OeM myocardial fibroblasts are consistent with clinical 
specimens and have provided a basis for the advancement of a cell specific 
strategy, targeting and regulating atypical MMP expression. This model was 
utilized in combination with a unique method to directly investigate miR-133a's 
ability to modulate MT1-MMP protein abundance. To achieve modulation, one of 
two bicistronic HIV-based Lentiviral Vectors allowed for delivery of a microRNA 
precursor to the fibroblasts in culture. 
Specific Aim 1: Demonstrate OeM fibroblasts have a unique phenotype 
compared to normal fibroblasts. 
Approach: The goal of this specific aim was to demonstrate key phenotypic 
differences in cultured myocardial fibroblasts isolated from the left ventricle of 
normal and DeM patients. This set of studies established differential steady-
state MT1-MMP protein abundance and activity in DeM fibroblasts. The 
elevated levels of MT1-MMP likely contribute to changes in matrix structure and 
function with DeM, therefore this aim established the relationship between the 
phenotypic alterations in normal and OeM fibroblasts. 
Specific Methods: Primary cultures of myocardial fibroblasts have been 
established using a validated outgrowth technique. Full thickness LV myocardial 
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samples were minced into several 2mm2 cubes under sterile conditions in a 
laminar flow hood, then transferred to cell culture flasks and allowed to adhere. 
Following a two week outgrowth period, these fibroblasts were sub-cultivated and 
used to establish primary fibroblast cultures. LV myocardial fibroblasts were 
maintained in culture in an identical fashion as previously described (preliminary 
studies). This has served as a test bed for the resolution of specific aim 1. 
Response Variables: The response variables were MT1-MMP protein 
abundance/activity, MT1-MMP mRNA levels, and MT1-MMP ribosomal 
distribution (methods and results in preliminary data section). 
Data Analysis: Comparisons between groups were made using the Student's t-
test (for pairwise comparisons) or two way analysis of variance (ANOVA) as 
appropriate. Statistical tests were performed using STATA (Intercooled STATA 
8, College Station, TX). Data are represented as mean +/- standard error of the 
mean. A p value of <0.05 was considered to be statistically significant. 
Specific Aim 2: Establish miR-133a as a post-transcriptional regulator 
of MT1-MMP. 
Approach: The goal of this specific aim was to confirm miR-133a as a direct 
post-transcriptional regulator of MT1-MMP protein abundance in normal and 
DCM myocardial fibroblasts. This set of studies demonstrated that Normal and 
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DCM primary myocardial fibroblasts can be transduced by viral vectors to over 
express miR-133a or anti-miR-133a. Furthermore, following viral transduction, 
the absence of an activated non-specific cellular stress response through 
quantification of IFNJ31, OAS1, OAS2, MX1, ISGF3y and IFITM1 mRNA levels 
was demonstrated in normal and DCM myocardial fibroblasts. Finally, this set of 
studies has begun to establish the mechanism by which miR-133a regulates 
MT1-MMP protein abundance by quantifying MT1-MMP transcript levels and 
ribosomal distribution. 
Specific Methods: 
In Vitro microRNA Modulation. To investigate miR-133a's ability to modulate 
MT1-MMP protein abundance, one of three bicistronic HIV-based Lentiviral 
Vectors was employed to deliver a microRNA precursor to the fibroblasts or a 
control-scrambled-sequence in the case of the vehicle control lentivector. This 
control consisted of a non-targeting precursor Scrambled sequence control 
hairpin in a pCDH-CMV-Scramble hairpin-EF1-copGFP lentivector (CD511 B-1; 
System Biosciences; Mountain View, CA). Over expression of miR-133a was 
achieved with the use of the PMICRORNA 1-hsa-mir-133a-1 vector (CS970MR-1 ; 
System Biosciences; Mountain View, CA). For knockdown of miR-133a, the anti-
miR-133a lentiviral construct (miRZip-133a anti-microRNA; CS970MZ-1; System 
Biosciences; Mountain View, CA) vector was utilized for the production of single-
stranded anti-microRNAs that competitively bind to endogenous miR-133a 
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targets, inhibiting interaction with mRNA. In addition, both vectors co-express a 
Green fluorescent protein, GFP, reporter under the control of independent 
promoters. Each virus will express an individual microRNA precursor in its native 
context while preserving hairpin structures to ensure biologically relevant 
interactions with endogenous processing machinery and regulatory partners. 
Transduction. Primary Human Cardiac Fibroblasts (2x105 Cells) were grown to 
70% confluence in sterile T-25 culture flasks (BO Falcon). After 24hrs, 
fibroblasts will be transduced with either a non-targeting precursor Scrambled 
sequence control hairpin, an hsa-miR-133a lentiviral construct or an anti-miR-
133a lentiviral construct with an MOl of 10 in a 1 X concentration of a 
transduction efficiency reagent, Transdux (L V850A-1; System Biosciences; 
Mountain View, CA) in Fibroblast Basal Media with added supplement mix and 
10% Fetal Bovine Serum. Three days following transduction, the media 
containing the introduced virus was aspirated from the culture flasks, cells were 
rinsed once with PBS and media was replaced with fresh complete growth 
media. Once the cells reached 1 00% confluence, they were trypsinized and split 
into T-75 culture flasks at a seeding density of 5,000 per cm2, To demonstrate 
feasibility of transduction, Figure 4-4 is representative of successful transduction 
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Figure 4-4. Confirmation of Transduction: Lack of GFP reporter expression in the first 
image confirms the absence of either vector, and positive GFP expression in the following two 
images indicate successful transduction. 
MT1-MMP mRNA levels. Five days following transduction, MT1-MMP mRNA 
expression was determined by RT-qPCR (methods previously described: 
Preliminary Studies). Because microRNAs post-transcriptionally regulate 
translation, no significant change was observed in both normal and OCM 
myocardial fibroblasts. As translational repression is an expected function of 
miR-133a on MT1-MMP, effects were not mediated by a change in MT1-MMP 
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Figure 4-5. MT1-MMP mRNA Expression Following Transduction. No statistical 
signifi ance was reached between groups. 
Interferon Response Detection. RNA interference (RNAi) is a fundamental 
mechanism of sequence-specific, double-stranded RNA mediated gene 
regulation. Although mammalian hosts have evolved defense mechanisms 
against double-stranded RNA, typically present as consequence of viral infection, 
these effects are not commonly present following microRNA delivery. Interferon 
activates a signaling cascade, culminating in transcriptional activation of multiple 
interferon stimulated genes. Many of these ISGs function in stress response 
pathways to mediate the cellular antiviral response; this will result in a global 
reduction of translation. Although multiple studies have demonstrated efficient 
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and specific silencing of gene expression with the use of chemically synthesized 
double-stranded small interfering RNAs (siRNA) or vector based short hairpin 
RNAs, increasing evidence reporting the potent induction of interferons (IFNs) 
and pro-inflammatory cytokines both in vitro and in vivo, therefore limiting the 
efficacy of their use58 . Alternatively, microRNAs possess a preserved hairpin 
structure known to ensure a biologically relevant interaction with endogenous 
processing machinery and regulatory partners, thereby limiting the possibilities of 
off-target interactions and activation of IFNs and inflammatory cytokines56. 
Therefore, to confirm the specificity of the RNAi knockdown phenotype or 
response, six genes associated with induction of an interferon response were 
examined by RT-qPCR following transduction by the CD511 virus, a control 
lentivector containing a scrambled sequence, the miR-133a lentivector or the ant-
miR-133a lentivector (methods previously discussed). The adherent, human 
firosarcoma cell line, HT1080, was utilized in the production of a positive 
interferon response control. The HT1080 cells were treated with 1,000 IU/mL 
Interferon Beta (BioAbChem, specific activity: 2.7x108 IU/mg) for 24 hours to elicit 
an interferon response55 . Interferon-~1 (IFN~1) is known to be produced by 
fibroblasts and possesses antiviral activity which is mainly involved in the innate 
immune response. The genes encoding 2'5'-0Iigoadenlylate synthetases (OAS1 
and OAS2) are important interferon-induced genes for the inhibition of cellular 
protein synthesis following viral infection. The product of the MX1 gene is a 
member of the interferon induced myxovirus resistance protein family, and 
participates in the innate host defense against RNA viruses, and was not 
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detected in either control IFN stimulated cells or experimental. As a virus was 
not utilized to stimulate the IFN response in control cells the absence of the MX1 
signal suggested that the interferon response was not previously stimulated by 
viral infection. ISGF3y is part of a cellular interferon receptor involved in 
interferon induced transcription regulation and stimulation. IFITM1, a member of 
the interferon inducible transmembrane proteins, mediates the anti-proliferation 
activity of interferon. As induction of an interferon response is defined as a 
robust increase in all of the following mRNAs55 , the observation that no 
significant induction of IFNJ31, OAS1, OAS2, MX1, ISGF3y and IFITM1 mRNA 
levels following microRNA transduction, suggested that the gene silencing 
induced by miR-133a was not associated with induction of a nonspecific 































































Figure 4-7. Interferon Response Detection. As induction of an interferon response is 
defined as a robust increase in all of the following mRNAs, the observation that no significant 
induction of IFNf31, OAS1, OAS2, MX1, ISGF3y and IFITM1 mRNA levels following microRNA 
transduction, suggested that the gene silencing induced by miR-133a was not associated with 
induction of a nonspecific interferon response. Groups were pooled (normal n=4, OeM n=5) 
and data shown as a ratio to non-transduced referent control. 
MT1-MMP 3'UTR Target Confirmation. To confirm miR-133a directly targets 
MT1-MMP's 3'UTR, a commercially available 3'UTR reporter vector (SwitchGear 
Genomics) was constructed by cloning the 3'UTR of the human MT1-MMP gene 
downstream of a luciferase open reading frame. This method essentially places 
luciferase expression under the direct control of MT1-MMP's 3'UTR. This allows 
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for the quantifiable determination of active translation specifically occurring. 
Therefore co-transfection of the reporter vector with a microRNA mimic that 
targets the inserted 3'UTR, will result in repression of luciferace translation. The 
adherent, human firosarcoma cell line, HT1080, was utilized in the target site 
confirmation within MT1-MMP's 3'UTR. HT1080 cells were co-transfected in a 
96-well plate with the LightSwitch MT1-MMP 3' UTR reporter GoClone plasmid or 
the empty 3'UTR vector, GAPDH 3'UTR or R_02 (random sequence) 3'UTR as 
controls, in combination with a miR-133a microRNA mimic or non-mammalian 
mRNA targeting microRNA mimic as a control. The empty 3'UTR vector 
contained only the luciferase gene (RenSP) and its constitutive promoter. This 
construct served as a positive control for the transfection because of its 
promoter. The GAPDH 3'UTR vector is a housekeeping control construct, and 
contained the 3'UTR from the housekeeping control gene GAPDH cloned 
downstream of the RenSP luciferase reporter. The random control sequence 
3'UTR vector construct contained non-conserved, non-genic, and non-repetitive 
human genomic fragments inserted downstream of the RenSP luciferase 
reporter. Reporter assays were performed at 24 hours following transfection with 
DharmaFECT -Duo transfection reagent by the LightSwitch Luciferase Assay 
system (SwitchGear Genomics) (Figure 4-8). Luminescence will be quantitated 
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Figure 4-8 . Overview of methods involved in confirmation of microRNA target recognition 
triplicate. The results of this study were a decrease in luminescence observed in 
cells co-transfected with the MT1-MMP 3' UTR reporter GoClone plasmid and 
the miR-133a microRNA mimic, and no significant change in controls, 
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Figure 4-9. Confirmation that miR-133a directly targets MT1 -MMP's 3'UTR in vitro. 
Data Analysis: Comparisons between groups were made using the Student's t-
test (for pairwise comparisons) or two way analysis of variance (ANOVA) as 
appropriate. Statistical tests were performed using STATA (Intercooled STATA 
8, College Station, TX). Data are represented as mean +/- standard error of the 
mean. A P value of <0.05 was considered to be statistically significant. 
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Specific Aim 3: Determine the effect of miR-133a modulation on 
phenotypic differences between normal and OeM fibroblasts. 
Approach: Over expression and knockdown of miR-133a in a normal cell may 
provide invaluable insight regarding its function on MT1-MMP and the defined 
phenotypic differences between normal and OCM; however, normalizing 
phenotype via modulation of miR-133a during pathological OeM is requisite for 
obtaining direct evidence regarding its role in the underlying pathogenesis. The 
goal of this specific aim is to determine the consequence of miR-133a modulation 
on the phenotypic differences defined in specific aim 1. 
Specific Methods: 
MT1-MMP protein abundance. Five days following transduction, the relative 
abundance of MT1-MMP protein was determined by immunoblotting (methods 
previously described: Preliminary Studies). It was found that when compared to 
respective referent controls, a reduction of MT1-MMP protein abundance was 
observed with miR-133a over expression as well as a significant increase in 
MT1-MMP protein abundance with miR-133a knockdown, in both normal (Figure 
4-10) and OCM (Figure 4-11) myocardial fibroblasts. 
Sample Sizes: Normal, n=4; DCM, n=5. Completion of this specific aim required 
four identical cultures of each cell type treated with the following: Transduction 
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efficiency reagent alone, control-scrambled-sequence lentivector, miR-133a 
precursor lentivector, and anti-miR-133a precursor lentivector. 
Results: It was observed that over expression of the miR-133a precursor 
resulted in decreased MT1-MMP protein abundance, while knockdown of miR-
133a by expression of the anti-microRNA-133a result in a dramatic increase of 
MT1-MMP protein abundance in Normal (Figure 4-10) and DeM (Figure 4-11) 
myocardial fibroblasts. Furthermore, Figure 4-12 demonstrates that by 
increasing miR-133a levels in DeM myocardial fibroblasts, aberrant MT1-MMP 
protein abundance may be returned to within normal range. 
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Figure 4-10. Normal MT1-MMP Protein Abundance. This graph is reflective of percent 
change in MT1-MMP protein abundance when compared to respective referent controls 
following transduction, and shows a reduction of MT1-MMP protein abundance with miR-133a 
over expression , and a significant increase of MT1-MMP protein abundance with miR-133a 
knockdown. (Normalized to Beta Actin) 
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Referent Control miR·133a anti-miR·133a 
Figure 4-11. OeM MT1-MMP Abundance. This graph is reflective of percent change in MT1 -
MMP protein abundance when compared to respective referent controls following 
transduction, and shows a reduction of MT1-MMP protein abundance with miR-133a over 
expression , and a significant increase of MT1-MMP protein abundance with miR-133a 
knockdown. (Normalized to Beta Actin) 
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Figure 4-12. miR-133a's Ability to Reduce Aberrant MT1-MMP Protein Abundance in 
OeM Myocardial Fibroblasts to within Normal Range. 
Data Analysis: Comparisons between groups were made using the Student's t-
test (for pairwise comparisons) or two way analysis of variance (ANOVA) as 
appropriate. Statistical tests were performed using STATA (Intercooled STATA 
8, College Station, TX). Data are represented as mean +/- standard error of the 
mean. A P value of <0.05 was considered to be statistically significant. 
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CHAPTER 5: FUTURE DIRECTIONS 
The following section will provide insight for future directions of this study as 
well as preliminary feasibility data to demonstrate that the proposed directions 
are achievable. 
Determination of Cell Functionality. A cause and effect relationship has been 
established between MMP activity and the LV remodeling process associated 
with DCM. Therefore, we will seek to determine a quantifiable assessment of the 
differential biological phenotype of DCM myocardial fibroblasts in respect to 
several determinants of ECM structure: cell proliferation, adhesion, and 
migration. 
Proliferation. Cells will be seeded at 1 ,000 cells per well of a 96 well clear 
bottom plate (Costar Flat bottom Cell bind Surface [Poly-D-Lysine] Cat# 3300, 
Corning, NY), and allowed to adhere overnight. The following day growth media 
will be aspirated and replaced with fresh complete media. CyQuant Direct Cell 
Proliferation Assay (Cat#C35011, Molecular probes) kit will then be used to 
determine cell number. The basis of the CyQUANT kit is the use of a green 
fluorescent dye, which exhibits strong fluorescence enhancement when bound to 
cellular nucleic acids. This kit will be allowed to equilibrate to room temperature 
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and the following will be mixed: PBS (97.50/0), Cyquant Direct nucleic acid stain 
(0.004%), and direct background suppressor (0.02%). 12 hours following the 
addition of fresh complete phenol-free fibroblast growth media, an equal volume 
of 2X Detection reagent will be added to the cells in the culture media (assay is 
compatible in media with or without serum). Cells will then be incubated for 1 
hour at 37C with 5% CO2• Following one hour incubation time, fluorescence will 
be read from the bottom of the well at 480/535 Ex/Em. This will then be repeated 
at 24, 36, 48, 60, 72, 84, and 96 hours. For each cell line, a standard curve will 
be generated by preparation of a serial dilution of cell numbers ranging from 500 
to 5,000. These cells will be allowed to adhere overnight, and then the cells will 
be assayed directly by CyQUANT. Fluorescence will then be read from the 
bottom of the well at 480/535 Ex/Em. Relative fluorescence correlates linearly 
with cell number. As a proof of concept, preliminary results from this assay have 
identified that proliferation rate is significantly higher in DCM myocardial 
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Figure 5-1. Cell Proliferation: OeM (n=5) myocardial fibroblast proliferation rate is 
significantly higher than normal (n=4) cells. 
Adhesion. Myocardial fibroblasts, 2,000 cells per well, will be seeded in 100 uL 
of complete growth media per well of a 96 well clear bottom plate (Costar Flat 
bottom Cell bind Surface [Poly-D-Lysine] Cat #3300, Corning, NY). Cells are 
then allowed to adhere by returning the plate to the incubator for 1 hour in 
standard tissue culture conditions. The plate will then be washed five times with 
room temperature PBS (with Ca2+/Mg2+) using a BioPlex Pro Plate Washing 
Station set to "Drip Fill" to achieve consistency in washes across plates. Each 
well will then be carefully aspirated so as to not disturb the cells, and 100 uL of 
complete, phenol-free fibroblast growth media will be added to the cells. Cells will 
then be fluorescently labeled with CyQUANT, and relative fluorescence will be 
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quantitated by microplate reader. Cell number will then be obtained by 
comparing relative fluorescence values to a standard curve made with a known 
dilution of cells (methods previously described: Proliferation). As a 
demonstration of feasibility, results from this assay have identified that cellular 
adhesion to a Poly-O-Lysine coated surface is significantly reduced in OCM 
myocardial fibroblasts (Figure 17). Combined, the results from both adhesion 
Cell Adhesion 









Figure 17. Cell Adhesion: Adhesion to a Poly-D-Lysine coated surface is reduced in DeM 
(n=5) myocardial fibroblasts when compared to normal (n=4). 
and proliferation assays suggest that a significant and stable transformation of 
fibroblast phenotype, and thereby function may occur within the myocardial ECM 
with the development of OCM. 
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Migration. Cell migration is a fundamental cell behavior critical for many 
physiological and pathological events, such as the inflammatory response and 
heart failure. To compare migration properties between normal and DCM 
myocardial fibroblasts, The Oris Cell Migration Assay will be performed. This is a 
multistep process that starts with the application of a mask to the bottom of the 
wells of a 96-well, Poly-D-Lysine coated, microplate. Next, a polymeric insert is 
fitted to the inside of the wells of the microplate. This insert prevents cells from 
seeding the inner analytic zone of the well when cells are added to the wells of 
the microplate. Myocardial fibroblasts (2x103 cells per well) will be seeded in 100 
uL of complete fibroblast growth media. After cell attachment has occurred, the 
inserts will be removed. Wells will then be gently washed with fibroblast growth 
media, and cells will then receive 100 uL of fresh complete fibroblast growth 
media. Plates will then be returned to the incubator, allowing the fibroblasts to 
freely migrate into the central analytic zone of the wells. Fibroblasts that have 
not migrated into the analytic zone are blocked from view by the mask initially 
applied to the plate bottom. Based on the results from the proliferation assay, 
the approximate doubling time of the myocardial fibroblasts in culture, is 24 to 48 
hours. Therefore, to avoid the chance of proliferation occurring during the 
migration period, the migrated fibroblasts will be quantified by CyQUANT assay, 
and cell number will be determined by standard curve (methods described in 
previous section: Proliferation) following 6 and 12 hour incubation times. Each 
assay will be performed in triplicate and the results will be averaged. The 
anticipated outcome of this study is an increase in density of fibroblasts on the 
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inner analytic zone in OeM when compared to normal, suggesting OeM 
myocardial fibroblasts have an increased migration rate. 
MT1-MMP Translational Efficiency. Following transduction, MT1-MMP 
translational efficiency was determined by ribosomal distribution (methods 
previously described: Preliminary Studies). It was observed in a subset sample 
size of 1 normal, 1 OeM and 1 OeM cell line transduced with the miR-133a 
lentivector, that following over expression of miR-133a, specifically MT1-MMP 
predominantly shifted from polyribosomal to monoribosomal fractions in OeM 
myocardial fibroblasts (Figure 4-6). 
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Figure 4-6. MT1-MMP and GAPDH Ribosomal mRNA Distribution. (n=1) 
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TNFa, IL-1 and IL-6 Stimulation and Gene Expression Analysis. The 
importance of pro-inflammatory mediators in the development of heart failure has 
recently become apparent. Following myocardial infarction (MI), the acute 
inflammatory phase serves initially to drive tissue repair and adaptation to 
injury45; however, prolonged expression of pro-inflammatory cytokines is 
detrimental and can lead to progressive heart failure51 . The pro-inflammatory 
cytokines: tumor necrosis factor a (TNFa), interleukin-1 (IL-1), and interleukin-6 
(IL-6), are key in this myocardial inflammatory response4 . Cardiomyocytes 
respond to many pro-inflammatory cytokines by undergoing apoptosis and/or 
hypertrophy, while myocardial fibroblasts undergo a phenotype change and 
endure increased proliferation and collagen turnover, contributing to the adverse 
post-MI remodeling that can ultimately lead to heart failure51 . Therefore, to 
demonstrate a differential response in mRNA expression patterns between 
normal (n=4) and OeM (n=5), an established concentration of purified 
recombinant pro-inflammatory cytokines TNFa (10ng/mL), IL-1 (100 pg/mL) and 
IL-6 (100 pg/mL), will be delivered to the cells in reduced serum fibroblast growth 
media for a 24 hour time period. Following stimulation, the cells will be collected 
as previously described (Preliminary Studies). Total RNA will then be isolated 
and pooled into either normal or DCM. Assessment and quantification will be 
performed by methods previously described (Preliminary Studies). One 
microgram of high-quality RNA from each pool will be reverse-transcribed to 
generate cDNA using an RT2 First Strand Kit (Cat#C-03, SABiosciences, 
Frederick, MD), and the cDNA will then be immediately assayed for gene 
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expression by quantitative PCR. To easily assess the expression of numerous 
genes from the RNA pools, a custom RT2 Profiler PCR Array (Custom Services; 
SABiosciences) has been designed to test 42 different genes, including 4 
housekeeping control genes, in a 96-well plate format. The generated cDNA will 
be diluted into RT2 qPCR Master Mix (Cat#PA-011, containing Hot-Start Taq 
polymerase and a SYBR Green/Fluorescein mix specific for Bio-Rad qPCR 
systems; SABiosciences), according to the manufacturer's instructions, and then 
applied to a 96-well PCR Array plate. PCR will be performed using a MyiQ 
Single-Color Real-Time PCR Detection System (Bio-Rad) with the following 
cycling parameters: initial denaturation for 10 minutes at 95°C was followed by 
40 cycles of 15 seconds at 95°C, 40 seconds at 55°C, and 30 seconds at 72°C. 
A melt curve will be established immediately following the conclusion of the 
cycling program to allow for confirmation of a single PCR product for each gene-
specific primer set (1 minute at 95°C, 2 minutes at 65°C, followed by 60 cycles of 
15 seconds at 65°C with an increase of 0.5°C per cycle). Negative controls will 
be included on each plate to verify the absence of genomic DNA contamination 
(no reverse transcription control) and the absence of overall DNA contamination 
in the PCR system and working environment (no template control). Ct values will 
then be determined and fold change in steady-state gene expression between 
normal and DCM myocardial fibroblast will be calculated using the previously 
described method. Fold expression values greater than 2.0 or less than 0.5 will 
be considered a significant change in gene expression. In addition, any gene 









may result in increased adhesion, while expression of the anti-miR-133a may 
result in decreased adhesion, in both normal and DeM myocardial fibroblasts. 
Migration. Five days following transduction, migration rate will be determined by 
methods previously described: Specific Aim 1. It is anticipated that following over 
expression of miR-133a may result in a reduced migration rate, while expression 
of the anti-miR-133a may result in increased migration in both normal and DeM 
myocardial fibroblasts. 
TNFa, IL-1 and IL-6 Stimulation and Gene Expression Analysis. Five days 
following transduction, the myocardial fibroblasts will be stimulated with pro-
inflammatory cytokines, and effects on expression of 42 functionally related 
mRNAs will be quantitated by methods previously described (ABOVE). It is 
anticipated that following over expression of miR-133a in DeM myocardial 
fibroblasts may return expression patterns to within normal ranges, while 
expression of the anti-miR-133a in normal myocardial fibroblasts may result in an 
expression pattern consistent with that observed in DeM. 
Response Variables: The response variables will be: cell adhesion, proliferation 
"and migration; and gene expression analysis following TNFa, IL-1 and IL-6 
stimulation. 
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CHAPTER 6: SUMMARY 
Outcomes from this set of investigations demonstrate translational regulation 
of a key proteolytic mediator of ECM remodeling, MT1-MMP, by miR-133a, and 
furthermore determine the effects of modification on the phenotypic differences 
observed in OCM myocardial fibroblasts. The stepwise approach: 1) defined the 
phenotypic differences associated with determinants of ECM structure and 
function in OCM myocardial fibroblasts; 2) established miR-133a as a post-
transcriptional regulator of MT1-MMP; and 3) demonstrated that in vitro 
modulation of miR-133a can alter the defined phenotypic differences in OCM 
myocardial fibroblasts. These studies contribute to a better understanding of the 
etiology of DCM disease, and identify a modifiable endogenous regulatory target 
that may provide the foundation for the development of novel therapeutics with 
the potential for returning DCM phenotypic differences to normal. 
This study has demonstrated translational regulation of MT1-MMP protein 
abundance by direct modulation of miR-133a in normal and OCM myocardial 
fibroblasts, without induction of an interleron response. Identification of the 
cellular and molecular pathways responsible for the specific alterations 
correlating with disease state holds diagnostic and therapeutic relevance for one 
of the most urgent public health problems in the United States. 
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